Floatz logo

SIMVASTATIN

Rhabdomyosarcoma

Emory UniversitySmall moleculePhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

59 Active assets in the Rhabdomyosarcoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Eisai Inc.
Phase 2BBB
Ipilimumab
Children's National Research Institute
Phase 2BB
CALCIUM PHOSPHATE
Children's Oncology Group
Phase 3BB
Irinotecan
Milton S. Hershey Medical Center
Phase 2BB
Eloxatin
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

SIMVASTATIN is also rated in:

HypercholesterolemiaDormant
BBB
Indicative ·
76 / 100
View asset →
psychotic disorderDormant
BBB
Indicative ·
75 / 100
View asset →
inherited lipid metabolism disorderDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →